We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318352

CAS#: 105816-04-4

Description: Nateglinide is a drug for the treatment of type 2 diabetes. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Price and Availability

Size Price Shipping out time Quantity
500mg USD 275 2 Weeks
1g USD 465 2 Weeks
2g USD 665 2 Weeks
5g USD 950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-09. Prices are subject to change without notice.

Nateglinide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318352
Name: Nateglinide
CAS#: 105816-04-4
Chemical Formula: C19H27NO3
Exact Mass: 317.1991
Molecular Weight: 317.4226
Elemental Analysis: C, 71.89; H, 8.57; N, 4.41; O, 15.12

Synonym: DJN 608; DJN-608l; DJN608; Nateglinide; Fastic; Starlix

IUPAC/Chemical Name: (R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid


InChi Code: InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

SMILES Code: O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005 Oct;59(10):1218-28. Review. PubMed PMID: 16178991.

2: Phillips LS, Dunning BE. Nateglinide (Starlix): update on a new antidiabetic agent. Int J Clin Pract. 2003 Jul-Aug;57(6):535-41. Review. PubMed PMID: 12918894.

3: Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3(6):797-807. Review. PubMed PMID: 18200800; PubMed Central PMCID: PMC2350129.

4: Israel MK, Istvan E, Baron MA. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4(6):1167-78. Review. PubMed PMID: 19337530; PubMed Central PMCID: PMC2663444.

5: Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108. Review. PubMed PMID: 17253883.